Literature DB >> 22955373

The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.

Giovanni Monaco1, Tim Vervliet, Haidar Akl, Geert Bultynck.   

Abstract

Anti-apoptotic Bcl-2-family members not only neutralize pro-apoptotic proteins but also directly regulate intracellular Ca(2+) signaling from the endoplasmic reticulum (ER), critically controlling cellular health, survival, and death initiation. Furthermore, distinct Bcl-2-family members may selectively regulate inositol 1,4,5-trisphosphate receptor (IP3R): Bcl-2 likely acts as an endogenous inhibitor of the IP3R, preventing pro-apoptotic Ca(2+) transients, while Bcl-XL likely acts as an endogenous IP3R-sensitizing protein promoting pro-survival Ca(2+) oscillations. Furthermore, distinct functional domains in Bcl-2 and Bcl-XL may underlie the divergence in IP3R regulation. The Bcl-2 homology (BH) 4 domain, which targets the central modulatory domain of the IP3R, is likely to be Bcl-2's determining factor. In contrast, the hydrophobic cleft targets the C-terminal Ca(2+)-channel tail and might be more crucial for Bcl-XL's function. Furthermore, one amino acid critically different in the sequence of Bcl-2's and Bcl-XL's BH4 domains underpins their selective effect on Ca(2+) signaling and distinct biological properties of Bcl-2 versus Bcl-XL. This difference is evolutionary conserved across five classes of vertebrates and may represent a fundamental divergence in their biological function. Moreover, these insights open novel avenues to selectively suppress malignant Bcl-2 function in cancer cells by targeting its BH4 domain, while maintaining essential Bcl-XL functions in normal cells. Thus, IP3R-derived molecules that mimic the BH4 domain's binding site on the IP3R may function synergistically with BH3-mimetic molecules selectivity suppressing Bcl-2's proto-oncogenic activity. Finally, a more general role for the BH4 domain on IP3Rs, rather than solely anti-apoptotic, may not be excluded as part of a complex network of molecular interactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955373     DOI: 10.1007/s00018-012-1118-y

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  150 in total

1.  The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R.

Authors:  Carl White; Chi Li; Jun Yang; Nataliya B Petrenko; Muniswamy Madesh; Craig B Thompson; J Kevin Foskett
Journal:  Nat Cell Biol       Date:  2005-09-18       Impact factor: 28.824

Review 2.  The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death.

Authors:  V Shoshan-Barmatz; A Israelson; D Brdiczka; S S Sheu
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

3.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

Authors:  Jing Deng; Nicole Carlson; Kunihiko Takeyama; Paola Dal Cin; Margaret Shipp; Anthony Letai
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

4.  The zebrafish bcl-2 homologue Nrz controls development during somitogenesis and gastrulation via apoptosis-dependent and -independent mechanisms.

Authors:  E Arnaud; K F Ferri; J Thibaut; Z Haftek-Terreau; A Aouacheria; D Le Guellec; T Lorca; G Gillet
Journal:  Cell Death Differ       Date:  2005-11-11       Impact factor: 15.828

5.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

6.  The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor.

Authors:  Yi-Ping Rong; Geert Bultynck; Ademuyiwa S Aromolaran; Fei Zhong; Jan B Parys; Humbert De Smedt; Gregory A Mignery; H Llewelyn Roderick; Martin D Bootman; Clark W Distelhorst
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

7.  Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes.

Authors:  M Lam; G Dubyak; L Chen; G Nuñez; R L Miesfeld; C W Distelhorst
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

8.  Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast.

Authors:  Q Xu; J C Reed
Journal:  Mol Cell       Date:  1998-02       Impact factor: 17.970

Review 9.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.

Authors:  M Vogler; D Dinsdale; M J S Dyer; G M Cohen
Journal:  Cell Death Differ       Date:  2008-09-19       Impact factor: 15.828

10.  Ribosome-free terminals of rough ER allow formation of STIM1 puncta and segregation of STIM1 from IP(3) receptors.

Authors:  Gyorgy Lur; Lee P Haynes; Ian A Prior; Oleg V Gerasimenko; Stefan Feske; Ole H Petersen; Robert D Burgoyne; Alexei V Tepikin
Journal:  Curr Biol       Date:  2009-09-17       Impact factor: 10.834

View more
  19 in total

Review 1.  Bcl-2 proteins and calcium signaling: complexity beneath the surface.

Authors:  T Vervliet; J B Parys; G Bultynck
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

2.  The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria.

Authors:  Giovanni Monaco; Elke Decrock; Nir Arbel; Alexander R van Vliet; Rita M La Rovere; Humbert De Smedt; Jan B Parys; Patrizia Agostinis; Luc Leybaert; Varda Shoshan-Barmatz; Geert Bultynck
Journal:  J Biol Chem       Date:  2015-02-13       Impact factor: 5.157

Review 3.  The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca²⁺-release channel.

Authors:  Tamara Vervloessem; David I Yule; Geert Bultynck; Jan B Parys
Journal:  Biochim Biophys Acta       Date:  2014-12-10

Review 4.  BH4 domain of Bcl-2 as a novel target for cancer therapy.

Authors:  Zhiqing Liu; Christopher Wild; Ye Ding; Na Ye; Haiying Chen; Eric A Wold; Jia Zhou
Journal:  Drug Discov Today       Date:  2015-11-26       Impact factor: 7.851

Review 5.  The role of Bcl-2 proteins in modulating neuronal Ca2+ signaling in health and in Alzheimer's disease.

Authors:  Manon Callens; Nina Kraskovskaya; Kristina Derevtsova; Wim Annaert; Geert Bultynck; Ilya Bezprozvanny; Tim Vervliet
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-03-09       Impact factor: 4.739

6.  Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain.

Authors:  Tim Vervliet; Irma Lemmens; Elien Vandermarliere; Elke Decrock; Hristina Ivanova; Giovanni Monaco; Vincenzo Sorrentino; Nael Nadif Kasri; Ludwig Missiaen; Lennart Martens; Humbert De Smedt; Luc Leybaert; Jan B Parys; Jan Tavernier; Geert Bultynck
Journal:  Sci Rep       Date:  2015-04-15       Impact factor: 4.379

7.  Glycine ameliorates mitochondrial dysfunction caused by ABT-199 in porcine oocytes.

Authors:  Sicong Yu; Lepeng Gao; Yang Song; Xin Ma; Shuang Liang; Hainan Lan; Xin Zheng; Suo Li
Journal:  J Anim Sci       Date:  2021-04-01       Impact factor: 3.159

8.  Sphingosine-1-phosphate and its effect on glucose deprivation/glucose reload stress: from gene expression to neuronal survival.

Authors:  Kinga Czubowicz; Magdalena Cieślik; Joanna Pyszko; Joanna B Strosznajder; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2014-07-24       Impact factor: 5.590

9.  Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.

Authors:  Giovanni Monaco; Elke Decrock; Koen Nuyts; Larry E Wagner; Tomas Luyten; Sergei V Strelkov; Ludwig Missiaen; Wim M De Borggraeve; Luc Leybaert; David I Yule; Humbert De Smedt; Jan B Parys; Geert Bultynck
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

10.  Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival.

Authors:  Frédérique Braun; Sophie de Carné Trécesson; Joséphine Bertin-Ciftci; Philippe Juin
Journal:  Cell Cycle       Date:  2013-08-13       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.